Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis
Talía Malagón, Karena D Volesky, Sheila Bouten, Claudie Laprise, Mariam El-Zein, Eduardo L Franco, Talía Malagón, Karena D Volesky, Sheila Bouten, Claudie Laprise, Mariam El-Zein, Eduardo L Franco
Abstract
Most women positive for human papillomavirus (HPV) are cytology normal. The optimal screen-management of these women is unclear given their risk of developing precancer. We performed a systematic review and meta-analysis of progression rates to precancer and cancer for HPV-positive, cytology normal women. We searched MEDLINE, EMBASE and Scopus for prospective studies measuring the cumulative incidence of precancer and cervical cancer in HPV-positive, cytology/histology normal women. Record screening was performed independently by two reviewers. We modeled the cumulative incidence over time using a multilevel random-effects meta-regression model. We used the model to predict HPV type-specific risks of precancer and cancer over follow-up. Data from 162 unique records were used in our analysis. The average incidence rate of cervical intraepithelial neoplasia grade 3 or cancer (CIN3+) in high-risk HPV positive but cytology/histology normal women was 1.0 per 100 women-years (95% CI: 1.0-1.1). This corresponds to an average cumulative risk at 1, 3 and 5 years of 2.1% (95% prediction interval 0.0-9.5), 4.3% (95% prediction interval 0.0-11.5) and 6.4% (95% prediction interval 0.0-13.5). HPV type was a strong predictor of the risk of oncogenic progression. There was substantial heterogeneity in the background precancer risk across studies (P-value < .0001). Our HPV type-specific progression risk estimates can help inform risk-based cervical cancer screening guidelines for HPV-positive women. However, precancer and cervical cancer risks are highly variable and may not be generalizable between populations.
Keywords: cervical cancer; cervical intraepithelial neoplasia; human papillomavirus; prospective; risk.
© 2020 UICC.
References
REFERENCES
- Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121:829-846.
- Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney: Cancer Council Australia; 2017.
- Public Health England. Cervical screening: implementation guide for primary HPV screening. London: Public Health England; 2019.
- Koliopoulos G, Nyaga VN, Santesso N, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8:CD008587.
- Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383:524-532.
- Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136:189-197.
- Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320:43-52.
- Dijkstra MG, van Niekerk D, Rijkaart DC, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev. 2014;23:55-63.
- Isidean SD, Mayrand MH, Ramanakumar AV, et al. Comparison of triage strategies for HPV-positive women: Canadian cervical cancer screening trial results. Cancer Epidemiol Biomarkers Prev. 2017;26:923-929.
- Machalek DA, Roberts JM, Garland SM, et al. Routine cervical screening by primary HPV testing: early findings in the renewed National Cervical Screening Program. Med J Aust. 2019;211:113-119.
- Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013;17:S56-S63.
- Polman NJ, Snijders PJF, Kenter GG, Berkhof J, Meijer C. HPV-based cervical screening: rationale, expectations and future perspectives of the new Dutch screening programme. Prev Med. 2019;119:108-117.
- Demarco M, Lorey TS, Fetterman B, et al. Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the Foundation of Risk-Based Cervical Screening Guidelines. J Low Genit Tract Dis. 2017;21:261-267.
- American Society for Colposcopy and Cervical Pathology. ASCCP Risk-Based Management Consensus Guidelines: New Recommendations for Public Comment. Rockville, MD: ASCCP; 2019.
- Cantor SB, Atkinson EN, Cardenas-Turanzas M, Benedet JL, Follen M, MacAulay C. Natural history of cervical intraepithelial neoplasia: a meta-analysis. Acta Cytol. 2005;49:405-415.
- Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.
- Ting J, Rositch AF, Taylor SM, et al. Worldwide incidence of cervical lesions: a systematic review. Epidemiol Infect. 2015;143:225-241.
- Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102:1478-1488.
- Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser cohort study. Cancer Epidemiol Biomarkers Prev. 2011;20:1398-1409.
- Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78-88.
- Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257.
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.
- Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1-48.
- Kirkwood B, Sterne J. Essential Medical Statistics. Hoboken, NJ: Wiley; 2003.
- Young DA, Zerbe GO, Hay WW Jr. Fieller's theorem, Scheffe simultaneous confidence intervals, and ratios of parameters of linear and nonlinear mixed-effects models. Biometrics. 1997;53:838-847.
- Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
- Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-129.
- Cook RD. Detection of influential observation in linear regression. Dent Tech. 1977;19:15-18.
- Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-672.
- Schiffman M, Hyun N, Raine-Bennett TR, et al. A cohort study of cervical screening using partial HPV typing and cytology triage. Int J Cancer. 2016;139:2606-2615.
- Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States. Int J Cancer. 2014;135:624-634.
- Chen H-C, Schiffman M, Lin C-Y, et al. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst. 2011;103:1387-1396.
- Bae J, Seo S-S, Park Y-S, et al. Natural history of persistent high-risk human papillomavirus infections in Korean women. Gynecol Oncol. 2009;115:75-80.
- Thomsen LT, Frederiksen K, Munk C, Junge J, Iftner T, Kjaer SK. Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytology. Int J Cancer. 2015;137:193-203.
- Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in The Netherlands. BMJ (Clin Res Ed). 2016;355:i4924.
- Hildesheim A, Gonzalez P, Kreimer AR, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016;215:212.e1-e15.
- Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349-2359.
- van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762-775.
- Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US preventive services task ForceUSPSTF modeling study: screening for cervical cancer in primary CareUSPSTF modeling study: screening for cervical cancer in primary care. JAMA. 2018;320:706-714.
- Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2:e96-e107.
- Landy R, Cheung LC, Schiffman M, et al. Challenges in risk estimation using routinely collected clinical data: the example of estimating cervical cancer risks from electronic health-records. Prev Med. 2018;111:429-435.
- Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079.
- Gage JC, Hunt WC, Schiffman M, et al. Similar risk patterns after cervical screening in two large U.S. populations: Implications for Clinical Guidelines. Obstet Gynecol. 2016;128:1248-1257.
- Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
- Cuzick J, Clavel C, Petry KU, et al. Overview of the European and north American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-1101.
- Mustafa RA, Santesso N, Khatib R, et al. Systematic reviews and meta-analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy. Int J Gynaecol Obstet. 2016;132:259-265.
Source: PubMed